South San Francisco-Based Proteolix Raises $45 Million in Second Round

South San Francisco -- Proteolix, a South San Francisco-based biopharmaceutical firm, said on Wednesday that it has raised $45 million in its second round of funding, which the company plans to use to expand clinical trials and further develop its pipeline. Delphi Ventures led the round, which also included participation from previous investors U.S. Venture Partners, Advanced Technology Ventures, Latterell Venture Partners and The Vertical Group. Proteolix is developing products to treat cancer and immune diseases based on new insights into the way in which cellular protein turnover controls cancer growth and immune responses. The company has now raised more than $63 million over the past three years.
http://www.proteolix.com/news.html